{"entity":{"id":"stingray-therapeutics","kind":"company","name":"Stingray Therapeutics","aka":["Stingray Therapeutics, Inc."],"tldr":"Stingray Therapeutics is a Houston company developing vizenpistat, a tablet designed to switch back on an early-warning part of the immune system that many tumours turn off. It is being tested with two immunotherapy antibodies in bowel cancer that is microsatellite stable.","summary":"Stingray Therapeutics develops vizenpistat (SR-8541A), an oral inhibitor of ENPP1, the enzyme that breaks down 2'3'-cGAMP before it can activate STING; the company describes blocking ENPP1 as a way to restore cGAS-STING innate immune signalling. Its website lists a phase 1 single-agent dose-escalation study in advanced solid tumours (NCT06063681) and a phase 1b/2 study with botensilimab and balstilimab in metastatic microsatellite stable colorectal cancer (NCT06589440), funded by a CPRIT grant and an NCI SBIR award. In fiscal year 2026 NCI awarded it USD 1,460,952 under SBIR award 5R44CA278144-04 for that colorectal programme.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.stingraytx.com/"},{"label":"NIH RePORTER: SBIR award 5R44CA278144-04","url":"https://reporter.nih.gov/project-details/11393170"},{"label":"ClinicalTrials.gov: phase 1 trial of SR-8541A (NCT06063681)","url":"https://clinicaltrials.gov/study/NCT06063681"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["vizenpistat"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06589440"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on stingraytx.com, NIH RePORTER and ClinicalTrials.gov on 4 November 2026. The company's ranking and safety claims are its own. No ENPP1 target record exists in the corpus."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"hq":"Houston, TX","country":"US","companyType":"biotech","website":"https://www.stingraytx.com/","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1460952,"source":"https://reporter.nih.gov/project-details/11393170","note":"NCI SBIR award (R44) 5R44CA278144-04: A Phase 1-2 clinical program for the treatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab"}]},"route":"/companies/stingray-therapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"vizenpistat","kind":"drug","name":"Vizenpistat","route":"/drugs/vizenpistat/"}],"trial":[{"id":"nct06589440","kind":"trial","name":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can","route":"/trials/nct06589440/"}]}}